NKp30/NCR3/CD337, His & Avi, Human
¥2600 | |
Z05692-100 | |
|
|
|
|
|
¥2600 | |
Z05692-100 | |
|
|
|
|
|
Species | Human | ||||||
Protein Construction |
|
||||||
Purity | > 95% as determined by BisTris PAGE | ||||||
Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||||
Expression System | HEK293 | ||||||
Theoretical Molecular Weight | 20 kDa | ||||||
Apparent Molecular Weight | Due to glycosylation, the protein migrates to 26-40 kDa based on Bis-Tris PAGE result. | ||||||
Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized NKp30/NCR3/CD337, His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Human B7-H6, hFc Tag with the EC50 of 58.6ng/ml determined by ELISA. »
Immobilized NKp30/NCR3/CD337, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-NKp30 Antibody, hFc Tag with the EC50 of 2.3ng/ml determined by ELISA. »
The purity of NKp30/NCR3/CD337, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
NKp30/NCR3/CD337, His & Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%. »
Human B7-H6, hFc Tag captured on CM5 Chip via Protein A can bind NKp30/NCR3/CD337, His & Avi, Human, His Tag with an affinity constant of 0.292 μM as determined in SPR assay (Biacore T200). »
Target Background | NKp30, along with NKp44 and NKp46, constitute a group of receptors termed 'Natural Cytotoxicity Receptors'. These receptors play a major role in triggering NK-mediated killing of most tumor cells lines.NKp30 stimulates NK cells cytotoxicity toward neighboring cells producing these ligands. It controls, for instance, NK cells cytotoxicity against tumor cells. Engagement of NCR3 by BAG6 also promotes myeloid dendritic cells (DC) maturation, both through killing DCs that did not acquire a mature phenotype, and inducing the release by NK cells of TNFA and IFNG which promote DC maturation. |
Synonyms | CD337; LY117; NCR3; NKp30; 1C7; MALS |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.